RBC Capital Maintains Sector Perform on PTC Therapeutics, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on PTC Therapeutics (NASDAQ:PTCT) and keeps the $52 price target unchanged.
May 24, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital analyst maintains Sector Perform rating on PTC Therapeutics (NASDAQ:PTCT) and maintains $52 price target.
The news is directly related to PTC Therapeutics as RBC Capital maintains its Sector Perform rating and $52 price target. This indicates that the analyst's view on the stock remains unchanged, which is likely to have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100